Jon Napitupulu

Biomea Fusion announced preclinical and clinical data for its investigational menin inhibitor, icovamenib, at the ATTD 2025 Conference. The...

Tenaya Therapeutics announced positive preclinical data for TN-201, its gene therapy candidate for MYBPC3-associated hypertrophic cardiomyopathy (HCM), published in...

Bionano Genomics and Greenwood Genetic Center (GGC) published a study in •Genome Research• demonstrating the use of optical genome...

PROCEPT BioRobotics announced positive three-month results from the WATER III trial, comparing its Aquablation therapy to laser enucleation for...

Clearside Biomedical announced the acceptance of six abstracts for presentation at the 2025 ARVO meeting. These abstracts cover topics...

Tonix Pharmaceuticals announced that the FDA will not require an advisory committee meeting for their New Drug Application (NDA)...

Opus Genetics announced positive Phase 3 results for its Phentolamine Ophthalmic Solution 0.75% in patients with dim light disturbances,...

Clearmind Medicine Inc. (Nasdaq: CMND) has shipped its novel psychedelic-derived drug candidate, CMND-100, to the United States for its...

Silexion Therapeutics has developed an expanded plan for SIL204, its next-generation siRNA candidate targeting KRAS-driven cancers. The company will...

Opthea Limited’s Phase 3 COAST trial for sozinibercept, a combination therapy with aflibercept for wet age-related macular degeneration (wet...